Dr. Chinglin Lai joined Apollomics in 2021 as the Senior Vice President of Biometrics. Dr. Lai has over 27 years of experience in drug development across a broad range of therapeutic areas. His experience is primarily in first-in-human studies through late-stage development for marketing approvals. Prior to Apollomics, Dr. Lai was a consultant providing statistical expertise to over 20 emerging and established pharmaceutical and biotech companies in the US and Asia. Previously, Dr. Lai held leadership positions at Jazz Pharmaceuticals, overseeing biostatistics, statistical programming, and data management functions for all portfolio products. Prior to Jazz, he worked at Intrabiotics Pharmaceuticals (2004-2005) and was a member of the core team for evaluating in-licensing opportunities, and Alza Corporation, where he contributed to the marketing approvals of 5 products in the US and EU. Dr. Lai received his B.S. in Mathematics from National Central University in Taiwan, and Ph.D. in Applied Statistics from the University of California, Riverside, with a concentration in experimental design.